Contraceptive Pathway and Contraception Continuation Rates
NCT ID: NCT03925116
Last Updated: 2022-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
400 participants
INTERVENTIONAL
2023-01-03
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles
NCT05139121
Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
NCT05505162
Study of Safety and Efficacy of an Oral Contraceptive
NCT00391807
Long-Acting Progestin Contraception and the Vaginal Microbiome
NCT02740998
Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive
NCT00362479
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients triaged to the pathway will be handed an electronic tablet questionnaire while they are waiting to see the physician/(Advanced practice nurse (APN). The tablet contains a link to bedside.org, a public website which reviews contraceptive options. Vital signs will be collected as per usual care and recorded on both the questionnaire and in the electronic medical record(EMR). Study personnel will be available to offer the patient additional information on their choice of contraception or assist them with the link for information. The completed survey will be printed and placed in the subject room for review by the physician/APN. A copy will be kept in the subject binder and another will be scanned into the EMR.
Patients triaged to usual care will wait for their physician without the pathway questionnaire and will be asked the usual questions by the MA which will be recorded in the EMR. Vital signs will be collected and recorded in the EMR.
The physician/APN will see the subject as usual, review either the questionnaire or the EMR, review contraception options and initiate the contraception.
At completion of the visit, all woman will be asked if she would complete a satisfaction survey for her visit. She will be called at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
usual care
women who present for birth control to the gynecology office will see their physician in the usual fashion for review, counseling and contraception decision/initiation.
Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation.
No interventions assigned to this group
Contraceptive pathway
Women who present for birth control to the gynecology office will be recognized by the front desk and offered a tablet which which will:
1. collect relevant medical history
2. provide educational material on birth control options
3. provide a link to bedsider.com for further information
They will then discuss the tablet information/history with the medical assistant, who will answer any remaining questions. They will then see the physician/APN.
Follow up phone call will be done at 2 weeks, 3, 6 and 12 months to discuss contraception initiation and continuation.
COntraceptive pathway
alternative way of aiding patients in deciding contraception method
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COntraceptive pathway
alternative way of aiding patients in deciding contraception method
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women able to read and write in English
Exclusion Criteria
* Women not sexually active with a male partner
* Women who intend to become pregnant in the next 12 months
18 Years
49 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Rutgers, The State University of New Jersey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adrian C Balica, MD
Associate Professor, Dept. Ob/Gyn, RWJMS
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian C Balica, MD
Role: PRINCIPAL_INVESTIGATOR
Rutgers Robert Wood Johnson Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Academic Building. 125 Paterson Street
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
public website with contraceptive information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro2018002901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.